SCHEMBL8720606

SCHEMBL8720606

CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
DPP7 Q9UHL4 1/20 0.50
ALDH1A1 P00352 1/20 0.50
PRCP P42785 2/20 0.46
CTSC P53634 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
XIAP P98170 1/20 0.42
REN P00797 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.40
TLR2 O60603 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24766527 1.00 L3MBTL1 (0.51) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL16899848 1.00 L3MBTL1 (0.51) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL8720605 1.00 L3MBTL1 (0.51) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30729278 1.00 L3MBTL1 (0.51) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30729237 1.00 L3MBTL1 (0.51) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL21677068 0.96 L3MBTL1 (0.50) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30051707 0.95 L3MBTL1 (0.47) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30051614 0.92 L3MBTL1 (0.45) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30052929 0.91 L3MBTL1 (0.46) L3MBTL1DPP7ALDH1A1PRCPCTSC
SCHEMBL30050989 0.90 DPP7 (0.44) L3MBTL1DPP7ALDH1A1PRCPCTSC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4659591-A1 TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT House Foods Group Inc. (JP) 2025-12-10 EP claimed
CN-120148690-A Preparation method and application of fermented soybean containing bioactive peptide 澳门科技大学 2025-06-13 CN claimed
CN-119007832-B Blood metabolism marker set for Alzheimer disease diagnosis and screening method and application thereof 复旦大学 2025-04-04 CN claimed
CN-119015834-A Carbon dioxide separation membrane and preparation method thereof 国家能源投资集团有限责任公司 2024-11-26 CN claimed
US-20240315296-A1 PEPTIDE COMPOUNDS FOR FLAVOR MODULATING CJ CHEILJEDANG CORPORATION (KR) 2024-09-26 US claimed
WO-2024162422-A1 TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT ハウス食品グループ本社株式会社 2024-08-08 WO claimed
EP-4364582-A1 PEPTIDE COMPOUNDS FOR FLAVOR MODULATING CJ Cheiljedang Corporation (KR) 2024-05-08 EP claimed
WO-2023277549-A1 PEPTIDE COMPOUNDS FOR FLAVOR MODULATING 씨제이제일제당 (주) 2023-01-05 WO claimed
EP-0197794-B1 PREPARATION OF PEPTIDES WITH C-TERMINAL PROLINE AMIDE SANKYO COMPANY LIMITED (JP) 1989-12-13 EP claimed
US-4709014-A Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1987-11-24 US claimed
EP-0197794-A2 Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1986-10-15 EP claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
US-12606634-B2 Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-04-21 US disclosed
US-20260027161-A1 BACTERIAL STRAINS FOR TREATING DISEASE MICROBA IP PTY LTD (AU) 2026-01-29 US disclosed
EP-4659591-A1 TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT House Foods Group Inc. (JP) 2025-12-10 EP disclosed
EP-0197794-B1 PREPARATION OF PEPTIDES WITH C-TERMINAL PROLINE AMIDE SANKYO COMPANY LIMITED (JP) 1989-12-13 EP disclosed
US-4709014-A Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1987-11-24 US disclosed
US-4709014-A Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1987-11-24 US disclosed
EP-0197794-A2 Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1986-10-15 EP disclosed
EP-0197794-A2 Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1986-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP L3MBTL1 184/4885DPP7 62/4885ALDH1A1 3596/4885
US-12606634-B2 Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 SIGLEC9, DSG1, VSIG8 L3MBTL1 1275/4885DPP7 2807/4885ALDH1A1 2747/4885
US-20260027161-A1 BACTERIAL STRAINS FOR TREATING DISEASE VIP, SI, ALPI L3MBTL1 1342/4885DPP7 225/4885ALDH1A1 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.